NSW2031 - Randwick - Scientia Clinical Research Ltd (COMPLETED)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)

VIC3168 - Clayton - Monash Medical Centre (COMPLETED)

QLD4575 - Sunshine Coast - Sunshine Coast University Private Hospital (COMPLETED)

NCT05253651

An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

NCT05086692

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (ABILITY-1)

NCT05067283

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (KANDLELIT-001)

NZNZ.8011 - Christchurch - New Zealand Clinical Research (COMPLETED)

NCT04929223

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (WO42758)

NCT04895709

A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (CA052-002)

NCT04585750

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

NCT04429542

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (BCA101X1101)

NCT03947385

A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (IDE196-001)

NCT03175224

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

ACTRN12626000350325

Phase I/Ib, Open-label, Dose Escalation and Expansion Study to Assess the safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of ACS2015, Non-viral Gene-modified CAR-T Cells in Patients with Advanced Solid Tumors Expressing EPHB4 (CARTiEr-E312)

ACTRN12625001151426

Not Applicable

Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy (HD-PRiMe)

ACTRN12625001005448

Not Applicable

Functional imaging-guided radiotherapy short course dose escalation in rectal adenocarcinoma: a feasibility study (FIGR-Short)

ACTRN12625000583448

Total Neoadjuvant Therapy for Organ Preservation in Early-Stage Low Rectal Cancer: The EARLY-TNT Trial (EARLY-TNT-Trial)

ACTRN12625000203459

An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (ENG19)

ACTRN12624001230549

An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.

ACTRN12624001164583

Not Applicable

Exploring the Utility of Peritoneal Tumour DNA to Detect Clinically Occult Peritoneal Metastasis in Locally Advanced Colon Cancer (DETECT-PM) in adults

ACTRN12623001333606

The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs) (CCaLM)

ACTRN12623000874617

Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (Biomarcer-2)

ACTRN12621001198819

Not Applicable

A Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (RESOLUTE)

ACTRN12620000757910

Not Applicable

Functional imaging-guided radiotherapy dose escalation in rectal adenocarcinoma: a feasibility study (FIGR-Rectal)

ACTRN12612000669897

Not Applicable

A single arm prospective study of the effect of preoperative chemoradiotherapy on sexual dysfunction in men with locally advanced rectal cancer

ACTRN12611000339954

Prospective Randomised Trial Of Extended Chemotherapy During The “Wait Period” Following Pre-Operative Neoadjuvant Chemoradiotherapy For Rectal Cancer (WAIT-study)

ACTRN12610000936022

Vitamin D supplementation prior to surgery for colorectal cancer.

NA

ACTRN12610000776000

Not Applicable

The use of novel protein biomarkers in predicting clinical outcomes in patients with localised and metastatic colorectal cancer

ACTRN12607000589482

Phase III randomised study of Brivanib Alaninate (BMS-582664) in combination with Cetuximab (Erbitux 'Registered trade mark') versus placebo in combination with Cetuximab (Erbitux 'Registered trade mark') in patients with K-Ras wild type tumours previously treated with combination chemotherapy for metastatic colorectal carcinoma to compare overall survival. (CO.20)

NA

ACTRN12605000459628

5HIAA as a marker for anti-vascular activity: change in serum 5HIAA in patients with advanced colorectal cancer receiving diclofenac or chemotherapy, and in control subjects without cancer receiving diclofenac (Hi5)

ACTRN12605000119695

Randomised Phase II trial of irinotecan with hyaluronic acid (HyCAMP) versus irinotecan as treatment for patients with metastatic colorectal cancer who have failed 5-FU based chemotherapy (CTA 2004) ............incidence of grade 3 or 4 diarrhoea. (HyCAMP-Phase-II)

NCT05462236

A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (AUM001-2001-MK3475-D65)

NCT03906331

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

ACTRN12617001190392

An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer (PIT-Study)

PD-1/PD-L1	34%
PD-1	27%
VEGF	24%
EGFR	23%
KRAS	14%
PD-L1	9%
PI3Kalpha	5%
MET	5%
ERBB2	5%
B7H3	4%
WRN	4%
VEGFA	4%
CEACAM5	3%
CCR8	3%
VEGFR1	3%
VEGFR2	3%
VEGFR3	3%
SMO	3%
HRAS G12C	3%
NRAS G12C	3%
MUC1	1%
GRPR	1%
Nectin4	1%
TGFBR2	1%
AR	1%
androgen axis	1%
LRRC15	1%
HDAC	1%
ERBB3	1%
FAK	1%
CTLA4	1%
prostaglandin DP1 receptor	1%
prostaglandin EP2	1%
prostaglandin EP2 receptor	1%
prostaglandin EP4 receptor	1%
CDK4	1%
CDK6	1%
ER	1%
oestrogen axis	1%
GPC3	1%
Trop2	1%
FR-alpha	1%
DPD	1%
orotate phosphoribosyltransferase	1%
CTNNB1	1%
BRAF	1%
RAF	1%
LGR5	1%
CAIX	1%
IL-2	1%
CDK7	1%
TIGIT	1%
TP53	1%
TP53 Y220C	1%
ALK	1%
MEK	1%
PKC	1%
ROS1	1%
FGFR	1%
FGFR1	1%
MNK	1%
RET	1%

ARTICANZ - Beta (ver 0.91)

Search results

Gastrointestinal (Lower)

Filters